Abstract
The golden era of drug discovery and development began to show cracks as research productivity has started to slump for such reasons that business analyst finds difficult to trace any specific point. To sort out this problem, this paper highlights not only few areas that are really exacerbating the situation such as imminent patent expiry of drugs, shrinking pipeline of NME, challenges from Regulatory Agencies, changing disease state and ageing population, worsened risk/reward ratio for research and development outlays, narrowing Return on Investment (ROI) for the Pharmaceutical R&D Industry and the related rise of cheaper generic alternatives, but also few approaches such as mergers and acquisitions, consolidation, diversification, in licensing, and strategic alliances that Industry is following to make Pharma business environment sustainable. Keywords: Aging population, branded generics, mergers and acquisition, new molecular entity, outsourcing, patent, pay for delay, personalised medicines, product hopping, regulatory challenges, return of investment, risk-reward ratio, technology-led discovery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Applied Clinical Research, Clinical Trials and Regulatory Affairs
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
